Journey Medical Corp (DERM)vsUnited Therapeutics Corporation (UTHR)
DERM
Journey Medical Corp
$5.97
-4.02%
HEALTHCARE · Cap: $166.03M
UTHR
United Therapeutics Corporation
$549.87
+0.40%
HEALTHCARE · Cap: $23.17B
Smart Verdict
WallStSmart Research — data-driven comparison
United Therapeutics Corporation generates 4801% more annual revenue ($3.17B vs $64.68M). UTHR leads profitability with a 40.6% profit margin vs -14.8%. UTHR earns a higher WallStSmart Score of 57/100 (C).
DERM
Avoid28
out of 100
Grade: F
UTHR
Buy57
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for DERM.
Margin of Safety
+2.5%
Fair Value
$487.82
Current Price
$549.87
$62.05 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 21.5% year-over-year
Keeps 41 of every $100 in revenue as profit
Strong operational efficiency at 41.7%
Safe zone — low bankruptcy risk
Every $100 of equity generates 22 in profit
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
ROE of -31.1% — below average capital efficiency
Expensive relative to growth rate
Revenue declined 1.6%
Earnings declined 12.2%
Comparative Analysis Report
WallStSmart ResearchBull Case : DERM
The strongest argument for DERM centers on Revenue Growth. Revenue growth of 21.5% demonstrates continued momentum.
Bull Case : UTHR
The strongest argument for UTHR centers on Profit Margin, Operating Margin, Altman Z-Score. Profitability is solid with margins at 40.6% and operating margin at 41.7%.
Bear Case : DERM
The primary concerns for DERM are EPS Growth, Market Cap, Piotroski F-Score.
Bear Case : UTHR
The primary concerns for UTHR are PEG Ratio, Revenue Growth, EPS Growth.
Key Dynamics to Monitor
DERM profiles as a growth stock while UTHR is a declining play — different risk/reward profiles.
DERM carries more volatility with a beta of 1.10 — expect wider price swings.
DERM is growing revenue faster at 21.5% — sustainability is the question.
UTHR generates stronger free cash flow (363M), providing more financial flexibility.
Bottom Line
UTHR scores higher overall (57/100 vs 28/100), backed by strong 40.6% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Journey Medical Corp
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Dermira, Inc., a biopharmaceutical company, develops and markets therapies for patients with dermatological diseases in the United States.
United Therapeutics Corporation
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
United Therapeutics Corporation, a biotechnology company, is dedicated to the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company is headquartered in Silver Spring, Maryland.
Visit Website →Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?